Compare SATL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATL | GHRS |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | Ireland |
| Employees | 154 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 947.2M |
| IPO Year | N/A | 2021 |
| Metric | SATL | GHRS |
|---|---|---|
| Price | $9.80 | $21.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $5.50 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 7.6M | 255.2K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.89 | N/A |
| Revenue Next Year | $56.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $10.67 |
| 52 Week High | $8.90 | $24.66 |
| Indicator | SATL | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 69.17 | 60.68 |
| Support Level | $3.17 | $12.41 |
| Resistance Level | N/A | $22.88 |
| Average True Range (ATR) | 0.83 | 1.33 |
| MACD | 0.20 | -0.07 |
| Stochastic Oscillator | 99.75 | 67.96 |
Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.